Welcome to our dedicated page for Lipella Pharmaceuticals news (Ticker: LIPO), a resource for investors and traders seeking the latest updates and insights on Lipella Pharmaceuticals stock.
Lipella Pharmaceuticals Inc. (LIPO) generates news primarily as a clinical-stage biotechnology company advancing reformulated drug candidates for diseases with significant unmet need. Company announcements focus on clinical trial progress, regulatory milestones, intellectual property developments, and changes in listing status for its common stock.
A major news theme for Lipella is its work in oral lichen planus (OLP)
Another recurring topic is Lipella’s broader pipeline for mucosal and urologic disorders, including programs in hemorrhagic cystitis and bladder cancer. The company has highlighted a U.S. patent covering MRI-based systems and methods for detecting interstitial cystitis and related lesions, noting its potential to enhance outcome assessments in ongoing development programs.
Investors following LIPO news will also see disclosures related to capital markets and corporate status. In 2025, Lipella announced that a Nasdaq Hearings Panel determined to delist its common stock from The Nasdaq Capital Market, with trading suspended and a subsequent Form 25 filed by Nasdaq. The company has issued a CEO letter to stockholders discussing the delisting, its clinical pipeline, financial position, and its intention to pursue relisting on a national exchange. Additional news items include participation in investor conferences and scientific meetings, where Lipella presents clinical data and corporate overviews.
This news feed allows readers to track Lipella’s clinical milestones, regulatory steps, intellectual property updates, and listing developments over time.
Lipella Pharmaceuticals (Nasdaq: LIPO), a clinical-stage biotech firm, announced a presentation by CEO Jonathan Kaufman at the Biotech Showcase 2023 in San Francisco on January 11, 2023, at 2:00 PM PST. The company focuses on reformulating existing drugs for new applications, targeting diseases with no FDA-approved therapies. Lipella aims to meet potential partners and investors at the event and is poised to release Phase 2a trial results for LP-10, addressing radiation-induced hemorrhagic cystitis, a severe condition.